Tatsiana Bylund
YOU?
Author Swipe
View article: Yeast Display Reveals Plentiful Mutations That Improve Fusion Peptide Vaccine-Elicited Antibodies Beyond 59% HIV-1 Neutralization Breadth
Yeast Display Reveals Plentiful Mutations That Improve Fusion Peptide Vaccine-Elicited Antibodies Beyond 59% HIV-1 Neutralization Breadth Open
Background/Objectives: Vaccine elicitation of antibodies with high HIV-1 neutralization breadth is a long-standing goal. Recently, the induction of such antibodies has been achieved at the fusion peptide site of vulnerability. Questions re…
View article: Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses Open
View article: Yeast Display Reveals Plentiful Mutations that Improve Fusion-Peptide Vaccine-Elicited Antibodies Beyond 59% HIV-1-Neutralization Breadth
Yeast Display Reveals Plentiful Mutations that Improve Fusion-Peptide Vaccine-Elicited Antibodies Beyond 59% HIV-1-Neutralization Breadth Open
Background/Objectives: Vaccine elicitation of antibodies with high HIV-1-neutralization breadth is a long-standing goal. Recently, induction of such antibodies has been achieved at the fusion peptide-site of vulnerability; questions remain…
View article: The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody
The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody Open
The N terminus of the H3 subtype of influenza virus hemagglutinin is ∼10 residues longer than the N termini of most other hemagglutinins. As conserved, exposed, and linear regions may be good vaccine targets, we investigated the vaccine ut…
View article: BRAVE: a highly accurate method for predicting HIV-1 antibody resistance using large language models for proteins
BRAVE: a highly accurate method for predicting HIV-1 antibody resistance using large language models for proteins Open
Motivation Broadly neutralizing antibodies (bNAbs) that target the envelope glycoprotein (Env) of human immunodeficiency virus-1 (HIV-1) have been utilized in clinical trials aimed at preventing and treating HIV-1 infections. However, the …
View article: Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies Open
Broadly neutralizing antibodies targeting the V2 apex of HIV-1 envelope are desired as vaccine design templates, but few have been described. Here, we report 11 lineages of V2 apex–neutralizing antibodies from simian-human immunodeficiency…
View article: VIProDesign: Viral Protein Panel Design for Highly Variable Viruses to Evaluate Immune Responses and Identify Broadly Neutralizing Antibodies
VIProDesign: Viral Protein Panel Design for Highly Variable Viruses to Evaluate Immune Responses and Identify Broadly Neutralizing Antibodies Open
Highly mutable viruses continuously evolve, with some posing major pandemic risks. However, standardized neutralization assays and up-to-date viral panels are often lacking, limiting evaluation of immunogens and identification of broadly n…
View article: The N Terminus of H3-Influenza Hemagglutinin as a Site-of-Vulnerability to Neutralizing Antibody
The N Terminus of H3-Influenza Hemagglutinin as a Site-of-Vulnerability to Neutralizing Antibody Open
View article: Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection
Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection Open
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the processes responsible for these obse…
View article: Rapid Emergence and Evolution of SARS-CoV-2 Variants in Advanced HIV Infection
Rapid Emergence and Evolution of SARS-CoV-2 Variants in Advanced HIV Infection Open
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions 1–4 , but the evolutionary processes underlyi…
View article: Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability Open
Lassa virus (LASV) infection is expanding outside its traditionally endemic areas in West Africa, posing a pandemic biothreat. LASV-neutralizing antibodies, moreover, have proven difficult to elicit. To gain insight into LASV neutralizatio…
View article: Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5
Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5 Open
The receptor-binding domain (RBD) of the SARS-CoV-2 spike is a primary target of neutralizing antibodies and a key component of licensed vaccines. Substantial mutations in RBD, however, enable current variants to escape immunogenicity gene…
View article: Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site
Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site Open
The HIV-1 fusion peptide (FP) represents a promising vaccine target, but global FP sequence diversity among circulating strains has limited anti-FP antibodies to ~60% neutralization breadth. Here we evolve the FP-targeting antibody VRC34.0…
View article: Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization
Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization Open
View article: HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide
HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide Open
Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates that typify HIV-1 transmission has been a long-sought goal. Success with prefusion-stabilized envelope trimers eliciting autologous neutralizing antibod…
View article: Vaccine elicitation and structural basis for antibody protection against alphaviruses
Vaccine elicitation and structural basis for antibody protection against alphaviruses Open
View article: Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency Open
Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain…
View article: Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1
Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1 Open
Conjugate-vaccine immunogens require three components: a carrier protein, an antigen, and a crosslinker, capable of coupling antigen to carrier protein, while preserving both T-cell responses from carrier protein and B-cell responses from …
View article: Cryo-EM structures of prefusion SIV envelope trimer
Cryo-EM structures of prefusion SIV envelope trimer Open
View article: Venom protection by broadly neutralizing antibody from a snakebite subject
Venom protection by broadly neutralizing antibody from a snakebite subject Open
Snake envenomation is a neglected tropical disease, causing >100,000 deaths and 300,000 permanent disabilities in humans annually. Could monoclonal antibody technology provide a solution? Here, we recover Centi-3FTX-D09, a potent broadly n…
View article: <i>C</i><sub>3</sub>-Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-HIV Activity
<i>C</i><sub>3</sub>-Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-HIV Activity Open
Lectins, carbohydrate-binding proteins of nonimmune origin, bind to carbohydrates and glycan shields present on the surfaces of cells and viral spike proteins. Lectins thus hold great promise as therapeutic and diagnostic proteins, exempli…
View article: Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability
Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability Open
Lassa virus (LASV) is responsible for 100,000-300,000 zoonotic infections annually and poses a threat to public health. Development of antibody-based therapeutics or vaccines has been challenging because neutralizing antibodies – even amon…
View article: Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces
Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces Open
View article: Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants Open
View article: N-terminal Transmembrane-Helix Epitope Tag for X-ray Crystallography and Electron Microscopy of Small Membrane Proteins
N-terminal Transmembrane-Helix Epitope Tag for X-ray Crystallography and Electron Microscopy of Small Membrane Proteins Open
View article: Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants
Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants Open
Since the start of the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 2 million deaths worldwide. Multiple vaccines have been deployed to date, but the contin…
View article: Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses Open
The COVID-19 pandemic highlights an urgent need for vaccines that confer protection from SARS-CoV-2 infection. One approach to an effective COVID-19 vaccine may be through the display of SARS-CoV-2 spikes on the surface of virus-like parti…
View article: Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B
Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B Open
Background: Respiratory syncytial virus (RSV) subtypes, A and B, co-circulate in annual epidemics and alternate in dominance. We have shown that a subtype A RSV fusion (F) glycoprotein, stabilized in its prefusion conformation by DS-Cav1 m…
View article: Crystal Structure of RSV strain B18537 Prefusion-stabilized glycoprotein F Variant DS-Cav1
Crystal Structure of RSV strain B18537 Prefusion-stabilized glycoprotein F Variant DS-Cav1 Open
We propose that structural differences in apical and equatorial sites-coupled to differently focused immune responses-provide a molecular explanation for observed differences in elicited subtype A and B neutralizing responses.
View article: Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529 Open